Exploring Vaccine Adjuvant R&D Within RSV Models

Time: 12:30 pm
day: Day Two

Details:

  • Preclinical studies showing effectiveness in neonates
  • Clinical development of the CAF®01 adjuvant
  • Immune profile of correct Th1/Th2 and antibody responses for optimal protection against RSV

Speakers: